Health
Convalescent plasma treatment added to Australian COVID-19 trials – Medical Xpress
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat …
Convalescent plasma has been introduced to the AustralaSian COVID-19 Trial (ASCOT) and Randomized, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia (REMAP-CAP) clinical trials in a bid to identify the best strategy to treat patients hospitalized with COVID-19.
The first patient was recruited to ASCOT earlier this week at The Royal Melbourne Hospital, while REMAP-CAP is on schedule to recruit critically ill patients in partnering Intensive Care Units in the com…
-
Business21 hours agoWhy Vault Minerals, Droneshield, Westgold Resources shares are climbing higher today
-
Noosa News23 hours agoQueenslanders to continue legal challenges against COVID-19 directives after successful appeal
-
Noosa News16 hours agoRacing Queensland responds to criticism of ‘deadliest’ greyhound track
-
General20 hours agoTrump’s AUKUS review coming soon. Will he stop the folly?